MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.77
+0.15
+1.03%
After Hours: 14.77 0 0.00% 16:00 12/13 EST
OPEN
14.66
PREV CLOSE
14.62
HIGH
15.60
LOW
14.22
VOLUME
80.26K
TURNOVER
--
52 WEEK HIGH
18.67
52 WEEK LOW
6.44
MARKET CAP
368.46M
P/E (TTM)
-13.9432
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VRCA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VRCA News

  • Is Verrica Pharmaceuticals Inc. (VRCA) A Good Stock To Buy?
  • Insider Monkey.11/29 03:43
  • ABEO, HEPA, EVH and KZIA among midday movers
  • Seeking Alpha - Article.11/27 17:42
  • The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
  • Benzinga.11/27 12:26
  • Verrica Pharmaceuticals moves forward with VP-102
  • Seeking Alpha - Article.11/27 12:17

More

Industry

Pharmaceuticals
-0.74%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About VRCA

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.
More

Webull offers Verrica Pharmaceuticals Inc (VRCA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.